New Standard for Borderline Resectable Pancreatic Cancer New Standard for Borderline Resectable Pancreatic Cancer
Neoadjuvant mFOLFIRINOX was associated with favorable overall survival compared to historical data, but the addition of hypofractionated radiotherapy did not improve outcomes.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | History of Medicine | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer